Prostate CancerComparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Introduction
Numerous studies have addressed the limited diagnostic accuracy of a patient's prostate-specific antigen (PSA) level and yet it remains the only widely adopted biomarker for prostate cancer (PCa) [1], [2], [3], [4].
Although sensitivity to detect increased risk of metastasis or death from PCa many years later may be unique [5], insufficient test specificity drives frequent prostate biopsies and a large proportion of benign biopsy specimens. Several additional biomarkers have been suggested, none of which have reached widespread clinical use. However, a few blood-based biomarkers have proved promising.
The Prostate Health Index (PHI) is an algorithm including the PSA isoform [−2]proPSA with total and free PSA. It has been demonstrated to increase predictive performance in several ethnically diverse cohorts for predicting PCa at biopsy or in radical prostatectomy specimens [6], [7], [8], [9], [10], [11].
Several other human kallikrein-related peptidases have been explored, and a four-kallikrein panel including kallikrein-related peptidase 2 (hK2), intact PSA, and free and total PSA has repeatedly been shown to predict prostate biopsy outcome in primarily European men with an elevated PSA level and to save a substantial number of biopsies [12], [13], [14], [15], [16].
The four-kallikrein (4K) panel and PHI represent improved tests for PCa that potentially can be of widespread clinical use. However, no study has compared the performance of these tests.
Section snippets
Study design
This observational study, using prospectively collected data, included men with blood samples drawn before a prostate biopsy resulting in cancer diagnosis (cases) or benign findings (controls). The study was designed to compare the diagnostic performance for predicting PCa using a base model containing total PSA value and age, PHI, and the 4K panel, respectively.
Study population
Men referred for PSA testing in laboratories in Stockholm County between 2010 and 2012 were invited to the population-based cohort
Results
Clinical characteristics of the study population are listed in Table 1 and Fig. 1. We identified 531 participants who had not undergone biopsy previously and whose PSA levels were between 3 and 15 ng/ml (271 cases and 260 controls). Of the cases, 134 (49%) were characterized as Gleason grade ≥7. Cases were older than controls (mean age: 66.0 yr vs 64.6 yr; p = 0.04). Concentrations of free PSA and [−2]proPSA differed significantly between groups (p < 0.001 and p = 0.038, respectively).
Discussion
We have compared the performance of two predictive models—PHI and a 4K panel—with each other and with a base model when applied to men who had not previously undergone a prostate biopsy with intermediately increased PSA level. We found that both PHI and the 4K panel increased predictive accuracy compared with the base model and that the PHI model and the 4K panel performed similarly for predicting both high-grade disease and all cancer.
Lilja and colleagues have repeatedly demonstrated that the
Conclusions
The 4K panel and PHI similarly improved discrimination when predicting PCa and high-grade PCa. Both are simple blood tests that can reduce the number of unnecessary biopsies compared with screening with total PSA, representing an important new option to reduce harm.
References (25)
- et al.
Age-specific reference ranges for serum prostate-specific antigen
Urology
(1995) - et al.
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range
J Urol
(2011) - et al.
Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer
Eur Urol
(2012) - et al.
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting
Eur Urol
(2011) - et al.
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study
Eur Urol
(2013) - et al.
Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003–2011
Eur Urol
(2013) - et al.
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
Eur Urol
(2010) - et al.
The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
JAMA
(1993) - et al.
Predictive properties of serum-prostate-specific antigen testing in a community-based setting
Arch Intern Med
(1996) - et al.
A systematic review of the diagnostic accuracy of prostate specific antigen
BMC Urol
(2009)
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
BMJ
From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer
BJU Int
Cited by (151)
The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics—Real-world Evidence from 2018 to 2022
2024, European Urology Open ScienceDevelopment and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer
2023, Urologic Oncology: Seminars and Original InvestigationsCombined Use of Magnetic Resonance Imaging and Biomarker Testing to Detect Clinically Significant Prostate Cancer
2023, Urologic Clinics of North AmericaProspective Multicenter Validation of the Stockholm3 Test in a Central European Cohort
2023, European Urology FocusMolecular Biomarkers for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis
2022, European Urology Open Science